Education
About Us
Working with TipRanks
Follow Us
HCW Biologics (HCWB)
NASDAQ:HCWB
HCWB Stock Chart & Stats
Day’s Range― - ―
52-Week Range$6.83 - $100.80
Previous CloseN/A
Volume102.01K
Average Volume (3M)7.50K
Market Cap
$7.75M
Enterprise Value$27.89M
Total Cash (Recent Filing)-$7.36M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.17
Next Earnings
May 08, 2025EPS Estimate
0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-31.50
Shares Outstanding1,123,353
10 Day Avg. Volume14,671
30 Day Avg. Volume7,495
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)3.29
Price to Cash Flow (P/CF)-1.00
P/FCF Ratio0.00
Enterprise Value/Market Cap3.60
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit29.07
Enterprise Value/Ebitda-0.77
Forecast
1Y Price Target
$3.00Price Target Upside-56.52% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
HCW Biologics News
PremiumCompany Announcements
HCW Biologics Announces Reverse Stock Split Approval
---
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressHCW Biologics announced the clearance of HCW9302 to enter a Phase 1 clinical trial in patients with moderate to severe alopecia areata.
Partnership ValidationA $7M upfront deal validates the potential of HCW Biologics' new discovery platform for multifunctional cytokines.
Pipeline AdvancementThe company raised $6.9M from a registered direct offering, providing operational breathing room and allowing pipeline advancement.
Bears Say
Financial ChallengesDespite recent capital influx, HCW Biologics has remaining legal expenses of $14.4M and may require further capital.
Net LossHCW Biologics reported a net loss and, despite recent capital influx, further capital will be required due to remaining legal expenses.
---
Ownership Overview
0.82%
Insiders
0.54% Mutual Funds
5.45% Other Institutional Investors
93.02% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
HCWB FAQ
What was HCW Biologics’s price range in the past 12 months?
HCW Biologics lowest stock price was $6.83 and its highest was $100.80 in the past 12 months.
What is HCW Biologics’s market cap?
HCW Biologics’s market cap is $7.75M.
When is HCW Biologics’s upcoming earnings report date?
HCW Biologics’s upcoming earnings report date is May 08, 2025 which is in 11 days.
How were HCW Biologics’s earnings last quarter?
HCW Biologics released its earnings results on Mar 28, 2025. The company reported -$3.2 earnings per share for the quarter, missing the consensus estimate of $3.6 by -$6.8.
Is HCW Biologics overvalued?
According to Wall Street analysts HCW Biologics’s price is currently Overvalued.
Does HCW Biologics pay dividends?
HCW Biologics does not currently pay dividends.
What is HCW Biologics’s EPS estimate?
HCW Biologics’s EPS estimate is 0.09.
How many shares outstanding does HCW Biologics have?
HCW Biologics has 1,123,353 shares outstanding.
What happened to HCW Biologics’s price movement after its last earnings report?
HCW Biologics reported an EPS of -$3.2 in its last earnings report, missing expectations of $3.6. Following the earnings report the stock price went down -0.826%.
Which hedge fund is a major shareholder of HCW Biologics?
Currently, no hedge funds are holding shares in HCWB
---
HCW Biologics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$3.00 (-56.52% Downside)
$3.00 (-56.52% Downside)
Crowd Wisdom
Neutral
Last 7 Days ▲ 4.5%
Last 30 Days ▼ 3.5%
Last 30 Days ▼ 3.5%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-88.18%
12-Months-Change
Fundamentals
Return on Equity
-897.37%
Trailing 12-Months
Asset Growth
6.04%
Trailing 12-Months
Company Description
HCW Biologics
HCW Biologics Inc., a preclinical stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases. The company's lead products include HCW9218, which is an injectable immunotherapeutic for patients with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as pulmonary fibrosis; and HCW9302 for auto-immune diseases, such as alopecia areata and metabolic diseases. It also develops HCW9201, a cell-based therapy that is in Phase II clinical trials for the treatment of patients with relapsed/refractory acute myeloid leukemia; and HCW9206 for the treatment of acute myeloid leukemia. The company was incorporated in 2018 and is headquartered in Miramar, Florida.
---
HCWB Stock 12 Month Forecast
Average Price Target
$3.00
▼(-56.52% Downside)
Technical Analysis
Carisma Therapeutics
―
PharmaCyte Biotech
―
Aprea Therapeutics
―
Dogwood Therapeutics
―
Turnstone Biologics Corp.
―
Best Analysts Covering HCWB
1 Year
1 Year Success Rate
2/13 ratings generated profit
1 Year Average Return
-44.22%
reiterated a buy rating 3 months ago
Copying Michael Okunewitch's trades and holding each position for 1 Year would result in 15.38% of your transactions generating a profit, with an average return of -44.22% per trade.
---